Neurovascular Injury

In acute ischemic retinal injury – including acute angle-closure glaucoma and retinal artery or vein occlusion – the initial vascular event triggers a cascade of programmed cell death that is not fully blocked by conventional anti-apoptotic approaches. Necroptosis, mediated by the RIPK1/RIPK3/MLKL pathway, is now recognised as a major RGC death mechanism in ischemic contexts. Critically, necroptotic cell death is accompanied by the release of damage-associated molecular patterns (DAMPs) that amplify neuroinflammation and extend vascular injury, compounding the initial insult. Demonstrating that a neuroprotective compound blocks both the primary cell-death mechanism and the secondary neurovascular damage – and that this protection is reflected in a functional visual endpoint – is essential for translational credibility.

For broader coverage of how ischemia-reperfusion drives retinal injury across models, see the Retinal Ischemia-Reperfusion Injury application page, and for RGC death mechanisms more broadly, see Retinal Ganglion Cell Pathology. For the glaucoma context of acute IOP elevation-induced ischemia, see Glaucoma and Glaucoma and Optic Nerve Neurodegeneration. Axon integrity is also at risk in acute ischemic events; for coverage of anterograde axonal degeneration downstream of RGC death, see Axon Degeneration. For structural consequences in the optic nerve, see Optic Nerve Damage.

Researchers studying vascular occlusion, stroke, or systemic vascular disease typically focus on histological, molecular, or MRI endpoints to characterise neurovascular injury. Yet these methods are often terminal, require specialist equipment, or cannot be repeated in the same animal over time. The retina offers a unique non-invasive window on CNS neurovascular health: because the retina shares barrier architecture and neurovascular unit organisation with the brain, retinal visual functional deficits reflect broader neurovascular injury severity. Quantifying this relationship requires a measurement approach that is rapid, non-surgical, and suitable for longitudinal use in the same animal cohort.

Neurovascular injuries including RVO affect approximately 16 per 100,000 people annually and are a leading cause of vision loss in working-age adults, presenting unmet therapeutic needs as noted in Colon Ortiz et al. (2022). For the broader CNS biomarker context in TBI and stroke, see the Trauma and Acute Injury parent application page.

Diabetic retinopathy is defined by the progressive loss of neurovascular unit integrity, beginning with iBRB disruption and culminating in neural degeneration and visual impairment. While anti-VEGF therapies have become the clinical standard for later-stage disease, a significant proportion of patients respond inadequately, suggesting that parallel non-VEGF pathways – including innate immune signalling – contribute independently to neurovascular injury, as documented in reviews such as Gardner et al. (2021, Progress in Retinal and Eye Research) and Tang et al. (2022, Neural Regeneration Research). Preclinical characterisation of innate immune-vascular pathology requires functional readouts that can detect iBRB-driven visual loss non-invasively, without confounding surgical or terminal measurements at each time point.

For a broader treatment of neuroinflammatory mechanisms in retinal disease, see the Neuroinflammation application page. For the diabetic retinopathy vascular endpoint context, see the Vascular and Metabolic Disease parent application page. The related cluster Retinal Ischemia-Reperfusion Injury covers overlapping mechanisms of acute iBRB disruption.

Characterising the time course of neurovascular injury in diabetic retinopathy models is complicated by the slow, progressive nature of the disease. Terminal end-points (histology, retinal flat-mounts, electrophysiology under anaesthesia) capture a single snapshot and require separate cohorts for each time point, multiplying animal use and introducing inter-cohort variability. Longitudinal in vivo functional measurements in the same animals would allow researchers to align the visual functional decline trajectory with molecular and structural changes (e.g. VEGF levels, tight junction protein loss, pericyte dropout) and identify early therapeutic windows for intervention. The standard of care for diabetic macular oedema relies on repeated intravitreal anti-VEGF injections, underscoring the clinical need for functional endpoints that can track treatment response over time, as noted in guidelines from NHS diabetic retinopathy treatment guidance.

For the broader longitudinal measurement methodology in diabetic retinopathy, see the Vascular and Metabolic Disease parent application page, which covers the full range of measurement approaches in detail. For neuroinflammatory drivers of disease progression, see the Neuroinflammation page.